Clinical Trial Update: Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed whether AZD9291 (osimertinib) alters the blood levels of simvastatin in patients with EGFR mutation-positive non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)
• Zocor (simvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-06-22